Anagrelide Retard vs. Placebo: Efficacy and Safety in "At-risk" Patients With Essential Thrombocythaemia

Clinical trial NCT01230775 · COMPLETED

Trial details

NCT number: NCT01230775
Sponsor: AOP Orphan Pharmaceuticals AG
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Essential Thrombocythaemia

Start date: 2010-12-01
Primary completion: 2015-01-01
Enrollment: 146

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.